OUR IMPACT

SOLUTIONS FOR increasing RESPIRATORY DISEASES

Diseases of the respiratory tract are increasing worldwide, driven by growing virus infections and inflammatory conditions. Today’s lifestyle, demographics, climate change, environmental effects and migration contribute to this evolution. As a consequence, diseases like allergic asthma, endemic virus infections and ARDS are growing, creating major challenges for humans, societies, and economies in almost all regions of the world. It is our objective to provide accessible and affordable therapeutic solutions for growing respiratory diseases to address these challenges on a global scale.

GLOBAL PANDEMIC PREPAREDNESS & RESPONSE

The COVID-19 pandemic revealed the severe impact of viral threats to humans and societies globally. In preparing for future pandemics new broadband antiviral therapies to contain virus spread are still missing especially for early pandemic phases. With our product development we strive to provide efficacious, safe and cost-effective antiviral therapeutics to contribute to future viral threats with pandemic potential globally.

INDUSTRIAL RECOMBINANT MANUFACTURING FOR BROAD AVAILABILITY

Several therapeutic proteins are obtained from human blood plasma, such as today’s AAT products. They need to be closely monitored for pathogen contamination, are prone to scarcity and ethical aspects need to be considered for plasma donation by people from middle- and low-income countries. Industrial recombinant production can overcome these challenges. We are committed to products made by industrial biotechnology, to contribute to a safer supply chain of urgently needed medicinal products, in conjunction with the principles of human equity.